Liquidia Technologies today announced that it will present findings from preclinical proof-of-concept studies conducted with its next generation, multivalent pneumococcal vaccine that is based on the company’s novel PRINT® (Particle Replication In Non-Wetting Templates) technology.
Results from these studies will be presented at the 32nd European Society for Paediatric Infectious Diseases (ESPID) Annual Meeting being held May 6-10, 2014 in Dublin, Ireland. ESPID 2014 will bring an estimated 3000 international researchers and clinicians who are committed to the treatment and prevention of infectious disease in children.
Shyam M. Rele, Ph.D., Liquidia’s Director, Polysaccharide Vaccines, will give an oral presentation in a special session titled Vaccines being held on May 9, 2014 in Hall H from 2:30 - 3:30pm. The title of the oral presentation is:
Next Generation Multivalent PRINT Nanoparticle Pneumococcal Vaccine: A New Paradigm for the Development of Capitally Efficient Vaccines Eliciting Potent B- and T-Cell Immune Responses.
Using the transformative PRINT technology, Liquidia has the ability to increase vaccine effectiveness by incorporating a smaller antigen load without the requirement of an additional adjuvant. This flexible approach provides a broad multi-antigen formulation capability and is being applied to preclinical proof-of-concept studies on Liquidia’s next generation pneumococcal vaccine to induce an enhanced immune response. If successful, the vaccine has the potential to broaden efficacy and manufacturing efficiencies that could translate to greater access to the vaccine by the global population.
Pneumonia kills approximately 1.1 million children annually under the age of five - more than any other illness. Nearly half of these deaths are caused by Streptococcus pneumoniae, a bacterium that has many variations globally and is becoming increasingly resistant to antibiotics.